PAVmed (PAVM) Cost of Revenue (2021 - 2025)

PAVmed's Cost of Revenue history runs 5 years deep, the most recent figure standing at $85000.0 for Q4 2025.

• On a quarterly basis, Cost of Revenue rose 77.08% year-over-year to $85000.0 in Q4 2025; TTM through Dec 2025 was $217000.0, a 95.72% decrease from a year earlier, with the FY2025 full-year figure at $218000.0, down 95.5% from the prior year.
• Cost of Revenue improved to $85000.0 in Q4 2025 per PAVM's latest filing, from $55000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.8 million in Q3 2023 and bottomed at $36000.0 in Q3 2024.
• The 5-year median for Cost of Revenue is $441000.0 (2021), against an average of $842941.2.
• Across the five-year window, Cost of Revenue surged 1029.17% in 2022 and plunged 97.94% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $441000.0 in 2021, then jumped by 266.89% to $1.6 million in 2022, then retreated by 0.43% to $1.6 million in 2023, then plunged by 97.02% to $48000.0 in 2024, then surged by 77.08% to $85000.0 in 2025.
• Per Business Quant, the three latest PAVM Cost of Revenue figures stand at $85000.0 (Q4 2025), $55000.0 (Q3 2025), and $41000.0 (Q2 2025).